Why does erythropoietin carry a boxed warning?

ESAs increase death, myocardial infarction, stroke, thromboembolism and vascular-access thrombosis, and in some cancers shorten survival or promote tumour progression, especially when haemoglobin is pushed above about 11 g/dL.

What haemoglobin level is targeted?

In CKD the aim is the lowest level that avoids transfusion, generally not exceeding about 11 g/dL, because CHOIR and CREATE showed higher targets add cardiovascular risk without benefit.

Is erythropoietin banned in sport?

Yes. It is on the WADA Prohibited List as a blood-doping agent; non-therapeutic use to raise haematocrit is prohibited and also carries thrombotic risk.

Does erythropoietin cure anaemia by itself?

It stimulates red-cell production but requires adequate iron; without sufficient iron the haemoglobin response is blunted, which is why it is given with iron supplementation.

EMA-approved

Erythropoietin (epoetin alfa) — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Erythropoietin (epoetin alfa) is a peptide catalogued under Immune. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Erythropoietin (epoetin alfa)?

Erythropoietin (epoetin alfa) is a recombinant form of the human hormone that drives red-blood-cell production, marketed as Epogen and Procrit. Unlike most peptides in this encyclopedia it is an FDA- and EMA-approved medicine, supported by decades of large randomized trials.

It is approved for anaemia of chronic kidney disease, chemotherapy-induced anaemia in patients with non-myeloid cancer, anaemia in zidovudine-treated HIV, and to reduce allogeneic transfusion in some surgical patients. As an erythropoiesis-stimulating agent (ESA) it carries an FDA boxed warning.

Erythropoietin is prohibited in and out of competition by WADA (blood doping, class S2); its use to raise haemoglobin in athletes is illegal doping, not a therapeutic use.

How does Erythropoietin (epoetin alfa) work?

Recombinant erythropoietin binds the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating their proliferation, differentiation and survival and thereby raising red-cell mass and haemoglobin.

Because it works upstream of red-cell production, its effect on haemoglobin takes days to weeks and depends on adequate iron stores.

What does the research say about Erythropoietin (epoetin alfa)?

In the original combined phase I/II trial, recombinant human erythropoietin produced a dose-dependent correction of the anaemia of end-stage renal disease and rendered nearly all previously transfusion-dependent dialysis patients transfusion-independent. ^[1]
In the CREATE trial, correcting anaemia toward normal haemoglobin improved several quality-of-life measures in CKD, although complete normalization produced no reduction in cardiovascular events. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Correction of the anemia of end-stage renal disease with recombinant human erythropoietin — Eschbach JW et al., The New England Journal of Medicine 1987. (Human phase I/II clinical trial)
[2] Correction of anemia with epoetin alfa in chronic kidney disease — Singh AK et al., The New England Journal of Medicine 2006. (Randomized controlled trial (CHOIR))
[3] Normalization of hemoglobin level in patients with chronic kidney disease and anemia — Drueke TB et al., The New England Journal of Medicine 2006. (Randomized controlled trial (CREATE))
[4] Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials — Bohlius J et al., Lancet 2009. (Meta-analysis of randomized trials)
[5] Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia — Bennett CL et al., JAMA 2008. (Meta-analysis)
[6] Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study — Leyland-Jones B et al., Journal of Clinical Oncology 2005. (Randomized controlled trial (survival))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In approved use, clinicians use the lowest dose sufficient to avoid red-cell transfusion and deliberately avoid normalizing or overshooting haemoglobin, because CHOIR, CREATE and TREAT showed higher targets add risk without benefit.

This is context only, not medical advice; ESA dosing is individualized by a prescriber against a capped haemoglobin target and monitored iron status.

Side effects & safety profile

ESAs carry an FDA boxed warning: they increase the risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access, and can shorten overall survival and/or increase tumour progression in some cancers. In CKD, targeting a higher haemoglobin (for example 13.5 g/dL) increased cardiovascular events and death versus a lower target in the CHOIR trial, so haemoglobin should not be driven above roughly 11 g/dL.

In oncology, a survival study in metastatic breast cancer (Leyland-Jones) and a class meta-analysis (Bohlius) linked ESAs to worse survival, and a JAMA analysis (Bennett) documented excess venous thromboembolism and mortality; ESAs should be used only for chemotherapy-induced anaemia and stopped after the chemotherapy course.

Erythropoietin is WADA-prohibited; raising haematocrit for performance also carries real thrombotic and cardiovascular danger.

Stacking & combinations

In legitimate therapy erythropoietin is paired with iron supplementation (oral or IV) rather than other peptides, because iron availability limits the erythropoietic response; there is no evidence-based stack beyond that.

Finding Erythropoietin (epoetin alfa) vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. It is approved for anaemia of chronic kidney disease, chemotherapy-induced anaemia in non-myeloid cancer, anaemia in zidovudine-treated HIV, and to reduce transfusion in certain surgeries, and is marketed as Epogen and Procrit.

References

[1] Correction of the anemia of end-stage renal disease with recombinant human erythropoietin — Eschbach JW et al., The New England Journal of Medicine 1987. PMID: 3537801. View sourceStudy: Human phase I/II clinical trialRecombinant human erythropoietin corrected the anaemia of ESRD in a dose-dependent way and eliminated transfusion dependence.
[2] Correction of anemia with epoetin alfa in chronic kidney disease — Singh AK et al., The New England Journal of Medicine 2006. PMID: 17108343. View sourceStudy: Randomized controlled trial (CHOIR)Targeting haemoglobin 13.5 g/dL with epoetin alfa increased the risk of the composite cardiovascular and death endpoint versus an 11.3 g/dL target.
[3] Normalization of hemoglobin level in patients with chronic kidney disease and anemia — Drueke TB et al., The New England Journal of Medicine 2006. PMID: 17108342. View sourceStudy: Randomized controlled trial (CREATE)Complete normalization of haemoglobin did not reduce cardiovascular events but improved some quality-of-life measures.
[4] Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials — Bohlius J et al., Lancet 2009. PMID: 19410717. View sourceStudy: Meta-analysis of randomized trialsESAs increased on-study mortality and worsened overall survival in cancer patients.
[5] Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia — Bennett CL et al., JAMA 2008. PMID: 18314434. View sourceStudy: Meta-analysisESA therapy for cancer-associated anaemia was associated with increased venous thromboembolism and mortality.
[6] Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study — Leyland-Jones B et al., Journal of Clinical Oncology 2005. PMID: 16087945. View sourceStudy: Randomized controlled trial (survival)Epoetin alfa targeting high-normal haemoglobin was associated with worse survival in metastatic breast cancer.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.